A multidisciplinary team of researchers led from Karolinska Institutet in Sweden have developed an anti-inflammatory drug molecule with a new mechanism of action.
By inhibiting a certain protein, the researchers were able to reduce the signals that trigger an inflammation. The study is published in Science and was done in collaboration with the University of Texas Medical Branch, Uppsala University and Stockholm University.
“We’ve developed a new drug molecule that inhibits inflammation,” says Professor Thomas Helleday, at the Department of Oncology-Pathology, Karolinska Institutet, Sweden, who co-led the study with Dr Torkild Visnes and Dr Armando Cázares-Körner. “It acts on a protein that we believe is a general mechanism for how inflammation arises in cells.”
The discovery is the result of many years of research by Thomas Helleday’s group on how DNA is repaired by the body. One of the objectives has been to fight cancer by targeting damage to the tumour cells’ DNA. Several breakthroughs have already been reported, which have led, amongst other things, to a new treatment for congenital breast and ovarian cancer using so-called PARP inhibitors, which has been available for some years.
Trials on mice
It was when developing a new molecule for inhibiting the enzyme that repairs oxygen damage to DNA that the researchers found, to their surprise, that it also dampened inflammation. It turned out that the enzyme OGG1, apart from repairing DNA, also triggers inflammation.
The inhibitor blocks the release of inflammatory proteins, such as TNF alpha. In trials on mice with acute pulmonary disease, the researchers succeeded in dampening the inflammation.
“This discovery could give rise to a new treatment for a very serious condition,” says Professor Helleday. “We’ll now be developing our OGG1 inhibitor and examining whether it can lead to new treatments for inflammatory diseases in order to cure or relieve diseases such as sepsis, COPD and severe asthma.”
The discovery was made in collaboration with Professor Istvan Boldogh from the University of Texas Medical Branch, USA.
The repair pathway on which OGG1 operates was discovered by Tomas Lindahl at Karolinska Institutet in the 1970s, an achievement that earned him the Nobel Prize in Chemistry in 2015.
Collaboration between several universities
The study was a collaboration between Karolinska Institutet, Uppsala University and Stockholm University in Sweden and the University of Texas Medical Branch, USA.
Learn more: New inflammation inhibitor discovered
The Latest on: Anti-inflammatory drug
[google_news title=”” keyword=”anti-inflammatory drug” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Anti-inflammatory drug
- Global Peptic Ulcer Drugs Market Size To Surpass US$ 6.1 Billion By 2032 | Exhibiting CAGR Of 2.65%on February 28, 2024 at 5:30 pm
The latest report by IMARC Group, titled“ Peptic Ulcer Drugs Market by Product Type (Proton Pump Inhibitors, Potassium-Competitive Acid Blo ...
- Anti-aging drug rapamycin found to improve immune function through endolysosomeson February 28, 2024 at 7:18 am
The therapeutic drug rapamycin, which is normally used in cancer therapy and after organ transplants, can extend the lifespan and health span of laboratory animals. Understanding how rapamycin extends ...
- Revolution via resolution: AbbVie pays $48M for OSE's preclinical chronic inflammation drugon February 28, 2024 at 1:25 am
AbbVie is talkin’ bout a resolution. The Big Pharma has bet $48 million on OSE Immunotherapeutics’ antibody platform, handing the biotech the upfront fee and dangling another $665 million in ...
- Nonsteroidal Anti-Inflammatory Drugs and Hypertensionon February 27, 2024 at 4:00 pm
NSAID doses were all within normal therapeutic anti-inflammatory dose ranges ... Normotensive patients (with or without antihypertensive medications) and uncontrolled hypertensives demonstrated ...
- Global Axial Spondyloarthritis Market to Reach USD 8.79 Billion by 2030 Amid Advancements in Treatment Modalities and Drug Classeson February 26, 2024 at 2:25 pm
Anti-Rheumatic Drugs, Glucocorticoids, Non-steroidal Anti-inflammatory Drugs (NSAIDs) End User: Hospitals, Clinics, Academic Research Institutes, Rehabilitation Centers Key Attributes: Zacks ...
- New York Attorney General Letitia James wants FDA to take action against asthma, allergy drug Singulairon February 22, 2024 at 4:40 pm
James says the anti-inflammatory drug has been linked to harmful behavioral and mental health issues in children.
- Inflammatory Bowel Disease Drug Modulates Gut Bacteriaon February 20, 2024 at 4:00 pm
Although it is one of the oldest medications used to treat patients with inflammatory ... a fatty acid molecule with anti-inflammatory properties. “These findings offer a way to identify IBD-SpA ...
- New insight into old IBD drug could improve treatmentson February 20, 2024 at 9:56 am
Although it is one of the oldest medications used to treat patients with inflammatory bowel disease (IBD) and an effective treatment for an associated arthritis condition called spondyloarthritis (SpA ...
- Researchers develop nanogel to deliver anti-inflammatory drugs for spinal cord injuryon February 19, 2024 at 4:00 pm
Using animal models, the study found that nanogels with the anti-inflammatory action drug rolipram successfully converted glial cells from a damaging to a protective state, contributing to the ...
via Bing News